Healthcare / Medical DevicesShenzhen
$41.10
+0.79 (+1.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $51.9M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.8B
P/E
132.6x
↑EV/EBITDA
43.9x
↑ROE
2.5%
↑Gross Margin
14.6%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.7%
FCF CAGR
—
FCF margin
11.7%
FCF / Net income
2.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $458.3M · net income $18.9M · FCF $53.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $458.3M | $458.3M | $477.4M | $533.7M | $547.1M |
| Net Income | $18.9M | $18.9M | $40.0M | $60.3M | $70.9M |
| EBITDA | $61.8M | $61.8M | $85.2M | $101.8M | $96.9M |
| EPS | 0.28 | 0.28 | 0.59 | 0.89 | 1.19 |
| Gross Margin | 14.6% | 14.6% | 17.8% | 21.3% | 22.4% |
| Operating Margin | 4.1% | 4.1% | 8.5% | 12.1% | 12.7% |
| Net Margin | 4.1% | 4.1% | 8.4% | 11.3% | 13.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 8.07 | 8.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $53.6M | $53.6M | $51.9M | $10.9M | $-52.5M |
| Returns | |||||
| ROE | 2.5% | 2.5% | 5.2% | 8.0% | 9.8% |
| Valuation | |||||
| P/E | 132.58 | 132.58 | 40.05 | 37.90 | 25.14 |
| EV/EBITDA | 43.94 | 43.94 | 16.96 | 19.78 | 17.34 |
| P/B | 3.67 | 3.67 | 2.10 | 3.05 | 2.46 |
| Growth & Yield | |||||
| Revenue Growth | -4.0% | -4.0% | -10.5% | -2.5% | — |
| EPS Growth | -52.7% | -52.7% | -33.7% | -25.7% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
135.9%
EPS terminal req.
$3.65
Spread vs growth
-188.6%
5Y implied EPS CAGR
73.9%
EPS terminal req.
$4.41
Spread vs growth
-126.6%
10Y implied EPS CAGR
38.3%
EPS terminal req.
$7.11
Spread vs growth
-91.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+40.6%
Start / end P/E
49.9x → 147.9x
EPS bridge
0.59 → 0.28
Residual
-103.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.